Trial document




drksid header

  DRKS00011887

Trial Description

start of 1:1-Block title

Title

First in man study to evaluate the safety, tolerability and preliminary efficacy of the
Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

FLYSYN-101

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

[---]*

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The purpose of this study is to characterize the safety profile and preliminary efficacy of FLYSYN as monotherapy in adult subjects with NPM1 positive acute myeloid leukemia (AML), ineligible for allogeneic hematopoietic stem cell transplantation in complete remission (CR) with molecular detection of minimal residual disease (MRD)

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00011887
  •   2017/03/17
  •   2016/05/13
  •   no
  •   Approved
  •   184/2016AMG1, Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2016-000236-17 
  •   NCT02789254  (clinicaltrials.gov)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C92.0 -  Acute myeloblastic leukaemia [AML]
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Cohort 1:
    Patient 1-3: FLYSYN 0.5 mg/m² body surface area (BSA) day 1

    Cohort 2:
    Patient 4-6: FLYSYN 0.5 mg/m² body surface area (BSA) day 1 FLYSYN 1.0 mg/m² BSA day 2

    Cohort 3:
    Patient 7-9: FLYSYN 0.5 mg/m² body surface area (BSA) day 1,
    FLYSYN 4.5 mg/m² BSA day 2

    Cohort 4:
    Patient 10-12 and 13-28*: FLYSYN 0.5 mg/m² body surface area (BSA) day 1, FLYSYN 14.5** mg/m² BSA day 2
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   I-II
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Incidence and severity of adverse events (AE) (CTCAE V4.03) until 28 days (i.e. Visit 7, day 29) after dosing

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Incidence and severity of adverse events (AE) (CTCAE V
4.03) until 180 days (i.e. Visit 11, day 180) after dosing
• Pharmacokinetics and pharmacodynamics
• Immunogenicity of FLYSYN based on both absolute (number
and percentage of subjects who develop HAMA/HAHA) and
semi-quantitative (HAMA/HAHA titer determination of
confirmed positive samples) assessments
• Absolute and percent change from baseline in measurements
of B, T, and NK cell populations and activation
• Absolute changes from baseline in laboratory parameters
• Change in cytokines from baseline
• Overall response rate, defined as MRD negativity or at least
one log step reduction
• Duration of response, time to MRD progression (log step), time
to relapse
• Absolute change from baseline in overall quality of life scores
(EORTC QLQ C-30)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
  • Medical Center 
  • Medical Center 
  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2017/02/15
  •   28
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

•Age ≥18 years at the time of voluntarily signing an IEC-approved informed consent, there is no upper age limit
•Diagnosis of AML with NPM1 mutation according to WHO criteria
•Confirmed FLT3 expression on leukemic cells
•Known mutational status of FLT3 (FLT3-ITD, FLT3-TKD, FLT3 wild type)
•Hematological CR (ANC count >1.000/µL, Thrombocytes > 100.000/µL), but MRD positivity after any therapy except allogeneic stem cell transplantation
•Life expectancy of > 3 months
•ECOG performance status ≤ 2
•Subject must be willing to receive transfusion of blood products
•Be willing and able to comply with the study protocol for the duration of the study
•Females of childbearing potential (FCBP) must undergo repetitive pregnancy testing (serum or urine) and results must be negative
•Reliable contraception should be maintained throughout the study and for 6 months after study treatment
•Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods
•Males (including those who have had a vasectomy) must use an effective barrier method of contraception throughout the study and for 6 months after study treatment if sexually active with a female of childbearing potential
•All subjects must:
ounderstand that the investigational product could have a potential teratogenic risk.
obe counseled about pregnancy precautions and risks of fetal exposure.
obe able to comply with all study-related procedures, medication use, and evaluations.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

The presence of ANY of the following criteria will exclude a patient from study enrollment:
•Patients proceeding to hematopoietic stem cell transplantation (suitable candidate and donor available, informed consent of patient)
•Pregnant or breast feeding females
•>5% blasts in bone marrow or extramedullary disease
•Treatment with monoclonal antibody within 3 months before treatment with FLYSYN or known immunoglobulin intolerance
•Known positivity for HIV, active HBV, HCV, or Hepatitis A infection
•No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment about study participation
•No consent for biobanking
•Presence of any medical/psychiatric condition or laboratory abnormalities which may limit full compliance with the study, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
•Prior history of malignancies, other than AML/myelodysplastic syndrome (MDS), unless the subject has (i) been free of the disease for ≥ 2 years. (ii) Exceptions include the following: Basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
•Patients receiving any medication listed in the Appendix IV “Prohibited Medications” (within 14 days prior to the first dose of study drug)
•Uncontrolled infection, e.g. infection progressing under adequate antimicrobial/antifungal/antiviral treatment
•Patients under ongoing treatment with another investigational medication or having been treated with an investigational medication within 14 days of screening
•Current treatment with immunosuppressive agents
•Systemic diseases (cardiovascular, renal, hepatic, etc.) that would prevent study treatment (e.g., creatinine >1.5x upper normal serum level; bilirubin, AST or AP >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Synimmune GmbH
    • Mr.  Dr.  Ludger  Grosse-Hovest 
    • Alte Landstrasse 42
    • 72072  Tübingen
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinische Kooperationseinheit Translationale Immunologie Deutsches Konsortium für Translationale Krebsforschung (DKTK) Deutsches Krebsforschungszentrum (DKFZ) Partnerstandort TuebingenMedizinische Klinik II
    • Mr.  Professor  Helmut R.  Salih 
    • Otfried-Müller-Str. 10
    • 72076  Tübingen
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinische Kooperationseinheit Translationale Immunologie Deutsches Konsortium für Translationale Krebsforschung (DKTK) Deutsches Krebsforschungszentrum (DKFZ) Partnerstandort TuebingenMedizinische Klinik II
    • Mr.  Professor  Helmut R.  Salih 
    • Otfried-Müller-Str. 10
    • 72076  Tübingen
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Synimmune GmbH
    • Mr.  Dr.  Ludger  Grosse-Hovest 
    • Alte Landstrasse 42
    • 72072  Tübingen
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.